bioAffinity Technologies Raises $3.2M in Public Offering

Event summary

  • bioAffinity Technologies closed a $3.2M public offering on June 18, 2026, issuing 4M shares at $0.80 each.
  • The offering included pre-funded warrants exercisable for common stock.
  • WallachBeth Capital acted as sole placement agent for the transaction.
  • Proceeds will support the company's noninvasive lung cancer detection technology, CyPath® Lung.

The big picture

The $3.2M raise underscores investor confidence in noninvasive cancer diagnostics, a sector gaining traction amid rising healthcare costs and demand for early detection. bioAffinity's ability to scale CyPath® Lung will hinge on reimbursement dynamics and competition from liquid biopsy players. The deal size, while modest, reflects the capital-intensive nature of bringing AI-driven diagnostic tools to market.

What we're watching

Commercialization Pace
How bioAffinity will deploy the $3.2M to accelerate CyPath® Lung adoption among high-risk patient populations.
Regulatory Dynamics
Whether the company can navigate CLIA oversight while expanding its LDT offerings.
Market Differentiation
The extent to which CyPath® Lung's 92% sensitivity and 99% NPV can sustain competitive advantage.

Related topics

Biotechnology